Journal Information

Statistics

Follow this link to access the full text of the article

PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
RR Barretoa, K Patelb, C Coombsc, N Shahd, T Eyree, W Wierdaf, P Ghiag, M Davidsh, W Jurczaki, A Matoj
a Eli Lilly and Company (Lilly), São Paulo, SP, Brazil
b Swedish Cancer Institute, Seattle, United States
c University of North Carolina at Chapel Hill, Chapel Hill, United States
d Medical College of Wisconsin, Milwaukee, United States
e Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom
f MD Anderson Cancer Center, Houston, United States
g Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
h Dana-Farber Cancer Institute and Harvard Medical School, Boston, United States
i Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
j Memorial Sloan Kettering Cancer Center, New York, United States
Ver más
Read
1204
Times
was read the article
518
Total PDF
686
Total HTML
Share statistics
Article information
ISSN: 25311379
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 May 17 9 26
2025 April 38 11 49
2025 March 46 13 59
2025 February 41 21 62
2025 January 33 23 56
2024 December 29 11 40
2024 November 27 18 45
2024 October 40 31 71
2024 September 41 19 60
2024 August 40 20 60
2024 July 46 24 70
2024 June 35 25 60
2024 May 40 21 61
2024 April 33 14 47
2024 March 24 24 48
2024 February 21 31 52
2024 January 12 11 23
2023 December 12 18 30
2023 November 15 21 36
2023 October 14 28 42
2023 September 11 20 31
2023 August 9 15 24
2023 July 9 6 15
2023 June 9 13 22
2023 May 9 13 22
2023 April 4 5 9
2023 March 4 6 10
2023 February 6 11 17
2023 January 5 4 9
2022 December 7 15 22
2022 November 6 11 17
2022 October 3 6 9
Show all

Follow this link to access the full text of the article

Idiomas
Hematology, Transfusion and Cell Therapy